PHOTO
Research has revealed 339 million people worldwide suffer from asthma, with around 1.3 million impacted in the UAE
CPhI Middle East and Africa, the leading global pharmaceutical event, will address the increasing prevalence of Chronic Respiratory Diseases (CRDs) in the region when the event returns to the Abu Dhabi National Exhibition Centre (ADNEC) from 16-18 September later this year.
CRDs including chronic obstructive pulmonary disease (COPD), asthma, respiratory allergies and occupational lung diseases, are becoming more prevalent in the Middle East region and leading to more opportunities for pharmaceutical firms.
Despite the introduction of 100% tax on tobacco products and the implementation of non-communicable disease initiatives, medicines are often either scarce or too expensive for patients and, in many instances, CRDs are not diagnosed.
“In the Middle East & Africa (MEA), CRDs are often left undiagnosed and untreated which has huge social and economic consequences. Successful pharmaceutical firms will underscore the importance of diagnosis and preventative treatment, while also working with government and health authorities to raise awareness of the issue,” said Cara Turner, Brand Director – Pharma, for UBM EMEA, organisers of CPhI.
According to the latest statistics from the Global Asthma Network, 339 million people globally are affected by asthma. The number of people impacted in the UAE is estimated at approximately 14% of the population, around 1.3 million people. Research by Fitch Solutions suggests the increasing incidence can be partly attributed to the rising economic prosperity of the Middle East region and the social transition towards a more urbanised lifestyle, further underscoring the opportunities for drug makers in the region.
CPhI Middle East & Africa is the region’s leading platform that brings together pharma ingredients, product manufacturers, suppliers and buyers covering every step of the pharma supply chain from drug research and discovery to finished dosage. Supported by Abu Dhabi Chamber of Commerce and Industry, the event is set to attract attendees from the Middle East and Africa and the rest of the world, with the MEA region accounting for 4% of the global pharma market.
Over 294 local, regional and international exhibitors from more than 35 countries are expected to attend the three-day showcase. In addition to the global network of exhibitors, the event is expected to attract over 4,900 participants, more than 50% of which will come from the MEA region.
“In addition to CRDs, we will be exploring and discussing several drivers impacting the pharmaceutical industry in the region. During the three-day event, a series of panel discussions will address the issues surrounding obesity and chronic diseases including diabetes and oncology; private medical insurance that all expatriate residents must carry; the growth of medical tourism in the region and the growth and development of the domestic manufacturing,” said Turner.
The exhibition space at CPhI is broken down into five distinct sectors of the pharmaceutical industry:
- CPhI: Brings together buyers, manufacturers and suppliers of pharmaceutical ingredients
- FDF: Meet with manufacturers from every aspect of the finished dosage supply chain
- ICSE: Connects the pharma community with CRO and CMO companies and technologies
- P-MEC: Showcases the newest pharmaceutical machinery, equipment and technology providers
- InnoPack: Hosts the latest innovations in packaging, integrated solutions and drug delivery systems
The exhibition will also feature Live Pharma Connect, a free service open to visitors and exhibitors allowing both parties to make pre-arranged pharma specific, mutually beneficial meetings during the event.
Running in parallel to the exhibition will be a range of content sessions addressing the latest trends in the market, a range of keynote addresses, as well as a host of networking opportunities.
The event takes place from 16-18 September 2019 at the Abu Dhabi National Exhibition Centre. For registration or further information please visitwww.cphi.com/mea.
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.
For more information visit: www.cphi.com
About UBM (and parent company Informa)
CPhI is organised by UBM, which in June 2018 combined with Informa PLC to become a leading B2B information services group and the largest B2B Events organiser in the world.
To learn more and for the latest news and information, visit www.ubm.com and www.informa.com
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
